Posted by The success story of Cantrixil, a potent anti-cancer drug candidate, has been followed on our blog for years, and now a new chapter in this journey has begun.
On March 13, 2026 Vivesto announced that the first dogs have been dosed in a pharmacokinetic and toxicology study of the drug candidate Cantrixil. The study aims to determine exposure, tolerability, and dosing strategy; early observations indicate that the treatment is well tolerated, with results expected in the summer of 2026. Cantrixil, which contains the molecule TRX-E-002-1 encapsulated in cyclodextrin, is being developed for the treatment of advanced cancers—particularly acute myeloid leukemia—and the program may also expand to include cancer treatment in dogs [1].
The previous milestones can be followed under these links:
[1] https://www.inderes.dk/en/releases/first-dogs-dosed-in-vivestos-pktoxicology-study-with-cantrixil